Authors
W Philip T James, Arne Astrup, Nick Finer, Jannik Hilsted, Peter Kopelman, Stephan Rössner, Wim HM Saris, Luc F Van Gaal
Publication date
2000/12/30
Journal
The Lancet
Volume
356
Issue
9248
Pages
2119-2125
Publisher
Elsevier
Description
Background
Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and to enhance the effects of a low-calorie diet for up to a year. We did a randomised, double-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over 2 years.
Methods
Eight European centres recruited 605 obese patients (body-mass index 30-45 kg/m2) for a 6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/day deficit programme based on measured resting metabolic rates. 467 (77%) patients with more than 5% weight loss were then randomly assigned 10 mg/day sibutramine (n=352) or placebo (n=115) for a further 18 months. Sibutramine was increased up to 20 mg/day if weight regain occurred. The primary outcome measure was the number of patients at year 2 maintaining at least 80% of the weight lost between baseline and …
Total citations
Scholar articles
WPT James, A Astrup, N Finer, J Hilsted, P Kopelman… - The Lancet, 2000
W Philip, T James, A Astrup, N Finer, J Hilsted… - Lancet, 2000
WPT Iames, A Astrup, N Finer, I Hilsted, P Kopelman - Lancet, 2000
JC Hilsted - Ugeskrift for læger, 1999